AMENDMENT TO LABOR/HHS/EDUCATION APPROPRIATIONS BILL
OFFERED BY MS. KAPTUR OF OHIO

On page 86 of the Committee Report, under the heading “CENTERS FOR MEDICARE AND MEDICAID SERVICES”, under the account “PROGRAM MANAGEMENT”, insert the following language directly after the table:

Drug Pricing Report.—The Committee directs the Secretary of Health and Human Services to submit a report to the Committee on Appropriations of the House of Representatives not later than 120 days after the date of the enactment of the Bill to which this Committee Report pertains regarding price changes of prescription drugs since 2008. The report should include comparative prescription drug prices (net of rebates) paid by the following programs for the 10 most frequently prescribed drugs and the 10 highest-cost drugs for each of the following:

(1) The Medicare program under part B of title XVIII of the Social Security Act.

(2) The Medicare prescription drug program under part D of title XVIII of the Social Security Act.
(3) The Medicaid program under title XIX of the Social Security Act.

(4) The Department of Veterans Affairs.

The report should also provide a breakdown of the comparative prices (net of rebates) for each of the 10 most frequently prescribed drugs and the 10 highest-cost drugs between ambulatory settings and retail settings.

Under Medicare Part D, the report should detail gross Part D drug costs and net Part D drug costs and the Direct and Indirect Remuneration for the 10 most frequently prescribed drugs and the 10 highest-cost drugs.

In addition, the report should include total annual costs due to prescription drugs to the Medicare program under part B of title XVIII of the Social Security Act, the Medicare prescription drug program under part D of title XVIII of such Act, and the Medicaid program under title XIX of such Act.

Finally, the report should list the drugs that have been registered for sale by the Food and Drug Administration (FDA) in the past five years that have benefited significantly from government grants or research subsidies in either the pre-clinical or clinical stages of development, as well as the price (net of rebates) and total spending in Medicare and Medicaid for each of those drugs.